Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC
Dong Min Kim, Mi Jin Kim, Jai-Hee Moon, Eun Young Lee, Jun Ki Hong, Seul Lee, Dong‐In Koh, Yae Seong Ryu, Seung Mi Kim, Soo-A Jung, Jae-Sik Shin, Joseph Kim, Yoon Sun Park, Seungwoo Hong, So Hee Lee, Joonyee Jung, Sang Soo Park, Do Yeon Kim, Eun Ho Kim, Hong-Rae Jeong, Ji Hee Gong, Ji-Eun Kim, Seung Chan Kim, Ha Na Yu, So Young Ki, Tae Won Kim, Dong‐Hoon Jin
Topics & Concepts
ErlotinibLung cancerErlotinib HydrochlorideEpidermal growth factor receptorCancer researchEGFR inhibitorsGrowth inhibitionIn vivoMedicineTyrosine kinaseTyrosine-kinase inhibitorCell growthCancerPharmacologyChemistryOncologyBiologyInternal medicineReceptorBiochemistryBiotechnologyLung Cancer Treatments and MutationsCytokine Signaling Pathways and InteractionsQuinazolinone synthesis and applications